19 Series A Biotech Investors — 19 Currently Deploying

Partner with visionary founders to build iconic B2B software companies. Early stage venture firm managed by former founders and operators investing in late seed through Series A.

Accelerating AI-native founders at the earliest stages. Lead early rounds in companies and founders building the future, providing that first check before others think you're onto …

NFX identifies and backs founders building companies with network effects. The fund emphasizes software development, founder support through content/tools, and emerging technologie…

Investing in dreams at the earliest stage, backing founders across marketplaces, fintech, developer tools, frontier tech, climate, and experimental ideas.

Investing in entrepreneurs building infrastructure and value chains around data, from the full data stack (infrastructure to applications) with belief that accurate, actionable dat…

Partner at inception with technically brilliant founders who see past impossible to inevitable. Invest in technical breakthroughs becoming world-changing companies, particularly in…

Founder-driven investing focused on bold teams and transformative ideas. Hands-on approach informed by past lives as founders and operators.

Invest in innovative founders tackling the world's complex challenges, partnering early to help transform ideas into world-class companies.

Correlation Ventures backs groundbreaking technology and data science companies that solve industry problems through rapid decision-making and industry-leading networks.

Speedinvest provides European startups with 'more expertise, connections, reach, and momentum' through specialist investment teams across six core sectors, backing companies from s…

Support domestic and international startups through capital provision and business collaboration, leveraging Dentsu Group's creative and strategic resources alongside global VC net…

Early-stage venture firm investing in technical founders solving hard engineering and science problems through the 'Super Evolution' — a non-linear approach to innovation enabled b…

Early-stage tech investments in the US and Israel, providing access and meaningful connections to help brilliant minds breakthrough.

Multi-stage venture capital firm that goes beyond traditional VC playbook by providing entrepreneurs support of a global ecosystem, connecting innovators everywhere.

Building breakthrough biotechs through partnerships with world-class life science entrepreneurs, translating groundbreaking science into life-changing medicines over 30+ years.

Back founders on a mission to industrialize scientific and technological progress.

Supporting ambitious founders to build category defining companies

Blue Ivy Ventures provides Yale alumni accredited investors access to diversified venture capital investments co-invested alongside leading VC firms, combining a curated annual fun…

How many series a biotech investors are actively deploying right now?

DryPowder tracks 19 series a biotech funds. Of these, 19 are currently deploying capital based on recent fund closes, portfolio activity, and partner signals. Use DryPowder's fund matching to see which ones fit your specific startup.

What check size do series a biotech VCs write?

Among 19 series a biotech funds on DryPowder, check sizes run from $250K–$5M. Ranges vary by fund size, vintage, and whether the fund leads rounds. Each fund profile shows check size detail and lead preference.

How do I get a meeting with a series a biotech VC?

A warm intro is still the fastest path. Most series a biotech VCs on DryPowder do accept cold outreach or direct applications, but response rates vary widely by fund. Before reaching out, use DryPowder's AI matching to get a fit score and specific talking points. Founders who lead with thesis-aligned framing get significantly better response rates than those sending the same deck to every fund on a list.

How long does a Series A process typically take?

Series A processes average 4-6 months. Unlike seed, you will navigate formal partner meetings, IC presentations, data room reviews, and reference calls. First meeting to term sheet alone takes 6-10 weeks at most firms. Running a compressed, competitive process where you approach all target investors in the same short window tends to produce faster decisions and better terms than a sequential approach.

How many series a biotech investors should I be talking to at once?

Most fundraisers recommend a parallel process: identify 20-40 target investors but approach your highest-fit funds first. Of the 19 series a biotech funds currently deploying, not all will match your specific stage and sector. Use fund matching to find your top 10-15, approach those first, collect feedback, then go wider. Going to every fund simultaneously without qualifying first burns bridges and dilutes the urgency that helps close a round.

How is DryPowder different from building a VC list on LinkedIn or Crunchbase?

The fund list you build on LinkedIn or Crunchbase is roughly the same list every other founder is building. DryPowder adds three things a manual search cannot: deployment signals (which funds have recently closed new vehicles and are actively writing checks), AI thesis matching (which of the 19 series a biotech funds actually fits your specific startup, ranked by fit), and verified partner contact details. The goal is 15 targeted, thesis-aligned pitches instead of 150 generic ones.